Barclays PLC Bio Atla, Inc. Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.37 - $3.92 $41,971 - $120,093	-30,636 Reduced 98.19%	566 $0
Q1 2024 May 15, 2024	SELL	$1.88 - $3.46 $55,819 - $102,730	-29,691 Reduced 48.76%	31,202 $107,000
Q4 2023 Feb 15, 2024	BUY	$1.27 - $3.18 $67,246 - $168,381	52,950 Added 666.62%	60,893 $149,000
Q3 2023 Nov 07, 2023	SELL	$1.7 - $3.07 $1,502 - $2,713	-884 Reduced 10.01%	7,943 $14,000
Q2 2023 Aug 03, 2023	BUY	$2.83 - $3.87 $24,980 - $34,160	8,827 New	8,827 $27,000
Q4 2022 Feb 13, 2023	BUY	$6.29 - $11.01 $223,062 - $390,447	35,463 Added 1890.35%	37,339 $308,000
Q3 2022 Nov 03, 2022	BUY	$2.94 - $11.87 $1,414 - $5,709	481 Added 34.48%	1,876 $14,000
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $139,069 - $351,265	-65,291 Reduced 97.91%	1,395 $4,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $292,084 - $1.25 Million	66,686 New	66,686 $333,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.